Inhibitory effects of parthenolide on the activity of NF-κB in multiple myeloma via targeting TRAF6

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 35, Issue 3, 2015, Pages 343-349

  Kong, Fan cong ^a   Zhang, Jing qiong ^b   Zeng, Chen ^a   Chen, Wen lan ^a   Ren, Wen xiang ^a   Yan, Guo xin ^a   Wang, Hong xiang ^b   Li, Qiu bai ^a   Chen, Zhi chao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Wuhan Central Hospital   (China)

Author keywords

nuclear factor B; parthenolide; tumor necrosis factor receptor associated factor 6; ubiquitination

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PARTHENOLIDE; RELA PROTEIN, HUMAN; SESQUITERPENE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; BLOOD; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; METABOLISM; MULTIPLE MYELOMA; TUMOR CELL LINE; UBIQUITINATION;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MULTIPLE MYELOMA; NF-KAPPA B; SESQUITERPENES; TNF RECEPTOR-ASSOCIATED FACTOR 6; TRANSCRIPTION FACTOR RELA; UBIQUITINATION;

EID: 84931261288     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-015-1435-0     Document Type: Article

References (24)

1. Fuchs O. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. Cardiovasc Hematol Disord Drug Targets, 2013,13(1):16–34
2. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol, 2000,18:621–663
3. Gasparini C, Celeghini C, Monasta L, et al. NF-kappaB pathways in hematological malignancies. Cell Mol Life Sci, 2014,71(11):2083–2102
4. Li ZW, Chen H, Campbell RA, et al. NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol, 2008,15(4):391–399
5. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell, 2007,12(2):115–130
6. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell, 2007,12(2):131–144
7. Smolinski AT, Pestka JJ. Comparative effects of the herbal constituent parthenolide (Feverfew) on lipopolysaccharide-induced inflammatory gene expression in murine spleen and liver. J Inflamm (Lond), 2005,2:6
8. Pajak B, Gajkowska B, Orzechowski A. Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells. Folia Histochem Cytobiol, 2008,46(2):129–135
9. Hewamana S, Lin TT, Jenkins C, et al. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clin Cancer Res, 2008,14(24):8102–8111
10. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood, 2005,105(11):4163–4169
11. Kong F, Chen Z, Li Q, et al. Inhibitory effects of parthenolide on the angiogenesis induced by human multiple myeloma cells and the mechanism. J Huazhong Univ Sci Technolog [Med Sci], 2008,28(5):525–530
12. Ghantous A, Sinjab A, Herceg Z et al. Parthenolide: from plant shoots to cancer roots. Drug Discov Today, 2013,18(17–18):894–905
13. Kwok BH, Koh B, Ndubuisi MI et al. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol, 2001,8(8):759–766
14. Zhang S, Lin ZN, Yang CF et al. Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells. Carcinogenesis, 2004,25(11):2191–2199
15. Guzman ML, Rossi RM, Neelakantan S, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood, 2007,110(13):4427–4435
16. Fuchs O. Transcription factor NF-kappaB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies. Curr Mol Pharmacol, 2010,3(3):98–122
17. Scheidereit C. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene, 2006,25(51):6685–6705
18. Gautheron J, Pescatore A, Fusco F, et al. Identification of a new NEMO/TRAF6 interface affected in incontinentia pigmenti pathology. Hum Mol Genet, 2010,19(16):3138–3149
19. Suvannasankha A, Crean CD, Shanmugam R et al. Antimyeloma effects of a sesquiterpene lactone parthenolide. Clin Cancer Res, 2008,14(6):1814–1822
20. Gunn EJ, Williams JT, Huynh DT, et al. The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma. Leuk Lymphoma, 2011,52(6):1085–1097
21. Gopal YN, Chanchorn E, Van Dyke MW. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Mol Cancer Ther, 2009,8(3):552–562
22. Naito A, Yoshida H, Nishioka E, et al. TRAF6-deficient mice display hypohidrotic ectodermal dysplasia. Proc Natl Acad Sci USA, 2002,99(13):8766–8771
23. Yang WL, Wang J, Chan CH, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science, 2009,325(5944):1134–1138
24. Lamothe B, Besse A, Campos AD, et al. Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J Biol Chem, 2007,282(6):4102–4112